Sunny Wang, MD | UCSF Helen Diller ...

Dr. Sunny Wang

Claim this profile

Veterans Affairs Medical Center - San Francisco

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
16 drugs studied

Area of expertise

1

Lung Cancer

Sunny Wang has run 7 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III
2

Non-Small Cell Lung Cancer

Sunny Wang has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage II
Stage IV
Stage III

Affiliated Hospitals

Image of trial facility.

Veterans Affairs Medical Center - San Francisco

Clinical Trials Sunny Wang is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about Sunny Wang

Clinical Trial Related

11 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Sunny Wang has experience with

  • Pembrolizumab
  • Carboplatin
  • Sotorasib
  • Biospecimen Collection
  • N-803 (ALT-803)
  • Crizotinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sunny Wang specialize in?

Is Sunny Wang currently recruiting for clinical trials?

Are there any treatments that Sunny Wang has studied deeply?

What is the best way to schedule an appointment with Sunny Wang?

What is the office address of Sunny Wang?

Is there any support for travel costs?